Gilead eyes new offers from a ‘place of energy’

Nonetheless driving the excessive of final 12 months’s twice-yearly HIV PrEP approval of lenacapavir as Yeztugo, Gilead Sciences is approaching dealmaking from a “place of energy” as a extra mature biopharma, in line with CEO Daniel O’Day.

“While you’re an organization that is cured a illness and confirmed healing potential in one other illness and are on the verge of ending an epidemic, you are sort of daring about your aspirations,” stated O’Day, referring to the corporate’s hepatitis C and HIV medicines.

Since O’Day joined Gilead from Roche in 2018, the California firm has constructed three major focus areas: virology, most cancers and irritation. In all three, Gilead’s current successes have given the pharma the luxurious of being selective within the exterior belongings it considers, O’Day defined.

“We maintain the bar very excessive scientifically,” the CEO informed journalists at a media occasion on the sidelines of the 2026 J.P. Morgan Healthcare Convention in San Francisco. “We have now the monetary capacity to herald essential medicines within the group, however they’ve acquired to suit our technique, and so they have to actually have a major affected person affect.”

Oncology was O’Day’s bread and butter at Roche, and a significant a part of his hiring at Gilead was an effort to spice up most cancers drug gross sales. Considered one of his first huge strikes was a $21 billion buyout of Immunomedics, which gave Gilead the anti-TROP agent Trodelvy. The pharma is now waiting for a possible launch of Trodelvy in first-line metastatic breast most cancers—although the blockbuster drug just lately failed to enhance progression-free survival in a part 3 trial—and an upcoming part 2 readout of the drug in non-small cell lung most cancers.

Relating to isolating progressive new most cancers candidates, Chief Medical Officer Dietmar Berger, M.D., Ph.D.—who joined a 12 months in the past—has his eyes on extra exact approaches.

“Gilead has classically been focusing so much on immuno-oncology,” Berger stated on the identical JPM occasion. 

The CMO stated he needs to “drive that a bit extra into direct tumor cell concentrating on,” whereas profiting from Gilead’s antibody-drug conjugate platform and relationship with cell remedy subsidiary Kite Pharma. Kite is poised to debut anito-cel, a CAR-T challenger to Johnson & Johnson’s Carvykti, in a number of myeloma this 12 months.

Cell remedy additionally comes into play in irritation, Berger stated, which is a extra nascent space for Gilead. However the pharma’s rising assortment of candidates hits “key nodes” of irritation, he added, like a STAT6 degrader via a $1.7 billion cope with Leo Pharma unveiled ultimately 12 months’s JPM.

“That takes us into kind 2 irritation and is admittedly an essential addition to the portfolio,” he stated, referring to the sort of irritation underlying situations like bronchial asthma and atopic dermatitis.

Whereas Gilead’s give attention to each most cancers and irritation is fueled extra by exterior innovation, the pharma is trying inward to construct on its lengthy historical past in virology. Gilead hopes to diversify the viruses it might probably deal with, with the pharma’s efforts lengthy centered on HIV and hepatitis. 

Berger pointed to December’s resolution to choose in to 2 genital herpes candidates from Meeting Biosciences to the tune of $35 million for instance of Gilead’s efforts to develop in virology. Gilead initially paid $100 million for the choice to license Meeting’s belongings in October 2023.

Associated areas of curiosity embrace respiratory viruses and rising viruses that would trigger future pandemics, Berger informed Fierce on the occasion.